Inflammatory Bowel Disease

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.

Throughout 2024, experts in the fields of gastroenterology and hepatology weighed in on cutting edge research, emerging trends and policies, as well as clinical innovations shaping the future of patient care.

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

For November’s Clostridioides difficile Awareness Month, the Peggy Lillis Foundation has launched a “See C. diff diagnosed” campaign to educate the public on the most common health care-associated infection, according to a press release.

PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.

PHILADELPHIA — Although there was no overall increased risk for flare 1 year after gender-affirming hormone therapy in patients with inflammatory bowel disease, active IBD and receiving testosterone increased the likelihood of a flare.

PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.

PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.

PHILADELPHIA — Primary sclerosing cholangitis is an independent risk factor for colorectal cancer, with an “almost three-times higher” risk among patients without inflammatory bowel disease vs. the general population, a researcher reported.